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PURPOSE. Targeted drug delivery to the ocular tissues remains a challenge. Biodegradable
intraocular implants allow prolonged controlled release of drugs directly into the eye. In this
study, we evaluated an anterior suprachoroidal polyurethane implant containing dexameth-
asone polyurethane dispersions (DX-PUD) as a drug delivery system in the rat model of
endotoxin-induced uveitis (EIU).
METHODS. In vitro drug release was studied using PUD implants containing 8%, 20%, and 30%
(wt/wt) DX. Cytotoxicity of the degradation products of DX-PUD was assessed on human ARPE-
19 cells using 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) test. Short-
term ocular biocompatibility of suprachoroidal DX-PUD implants was evaluated in normal rat
eyes. Endotoxin-induced uveitis was then induced in rat eyes preimplanted with DX-PUD.
Clinical examination was performed at 24 hours; eyes were used to assess inflammatory cell
infiltration and macrophage/microglial activation. Cytokine and chemokine expression in the
iris/ciliary body and in the retina was investigated using quantitative PCR. Feasibility of anterior
suprachoroidal PUD implantation was also tested using postmortem human eyes.
RESULTS. A burst release was followed by a sustained controlled release of DX from PUD
implants. By-products of the DX-PUD were not toxic to human ARPE-19 cells or to rat ocular
tissues. Dexamethasone-PUD implants prevented EIU in rat eyes, reducing inflammatory cell
infiltration and inhibiting macrophage/microglial activation. Dexamethasone-PUD downreg-
ulated proinflammatory cytokines/chemokines (IL-1b, IL-6, cytokine-induced neutrophil
chemoattractant [CINC]) and inducible nitric oxide synthase (iNOS) and upregulated IL-10
anti-inflammatory cytokine. Polyurethane dispersion was successfully implanted into
postmortem human eyes.
CONCLUSIONS. Dexamethasone-PUD implanted in the anterior suprachoroidal space may be of
interest in the treatment of intraocular inflammation.
Keywords: polyurethane, implant, suprachoroidal space, drug delivery, endotoxin-induced
uveitis
The treatment of intraocular inflammation, such as anterior,intermediate, and/or posterior uveitis, requires therapeutic
concentrations of drugs for a prolonged period. However,
ocular static barriers (cornea, sclera, blood–aqueous and
blood–retinal barriers) and ocular dynamic barriers (tear
dilution, conjunctival and choroidal blood flow),1 as well as
efflux pumps, limit the drug access to ocular tissues.2
Recently, intraocular implants based on biodegradable and
nonbiodegradable polymers incorporating drugs have been
used to treat ocular diseases. The nonbiodegradable implant-
able devices containing ganciclovir or fluocinolone acetonide
(Vitrasert and Retisert, respectively; Bausch & Lomb, Rochester,
NY, USA) have been approved for the treatment of cytomeg-
alovirus retinitis and chronic noninfectious posterior uveitis,
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respectively. The biodegradable implants composed of poly(-
lactic-co-glycolic acid) and dexamethasone (DX) (Ozurdex;
Allergan, Irvine, CA, USA) have also been approved for the
treatment of persistent macular edema following retinal vein
occlusion, diabetic macular edema, and noninfectious posteri-
or uveitis.3–5 These implants release therapeutic concentra-
tions of the drugs into the target site for a prolonged period,
overcome the natural ocular barriers, and reduce systemic side
effects, although glucocorticoid-incorporated delivery systems
may cause cataract and intraocular pressure elevation.6–8
Developing minimally invasive and long-acting intraocular
implants based on biodegradable polymers is the focus of
research for the treatment of the vitreoretinal disorders.9
Suprachoroidal space (SCS) provides a large potential anatomic
space for drug delivery. Suprachoroidal injection has shown a
significant improvement of drug transport only to adjacent
tissues, the choroid and retina, in animal models when
compared with intravitreal and subconjunctival administra-
tion.10–12 Implants composed of biodegradable polyurethane
were previously elaborated on, and we demonstrated their
ocular biocompatibility, as they induce neither inflammatory
responses in the eye nor alterations of the retinal architec-
ture.13 We previously showed that polyurethane implants
releasing DX inhibited local inflammatory response and
angiogenesis in a murine model for a prolonged period.14
In this study, we demonstrate the ocular biocompatibility of
DX-loaded polyurethane implants and of their degradation
products. These implants can be successfully inserted into the
supraciliary space or into the SCS facing either the posterior or
peripheral retina of rat eyes and human eyes. A polyurethane
thin sheet containing DX implanted in the anterior SCS
prevents ocular inflammation in rat endotoxin-induced uveitis,
a model of acute anterior uveitis affecting also the posterior
segment. Biocompatible and biodegradable polyurethane
suprachoroidal implants could be used as targeted drug
delivery systems for ocular diseases.
METHODS
Preparation of Dexamethasone-Loaded
Polyurethane Implants
Aqueous polyurethane dispersions (PUD) were prepared as
previously described.15 This chemical procedure was success-
ful in producing polyurethane dispersions with solid content of
approximately 20%. The composition of the PUD is shown in
Table 1. Polymeric films were produced by casting the
dispersions in a Teflon mold and allowing them to dry at
room temperature for 1 week. Films were then placed in an
oven at 608C for 24 hours. Different amounts of DX (Sigma-
Aldrich, Saint Quentin Fallavier, France) (6.0, 18.8, and 29 mg)
were incorporated into the polymer by dispersing them in 2
mL PUD prior to casting the films to yield materials having 8%,
20%, or 30% (wt/wt) of the drug. The dried sheet-like films
(Fig. 1A, approximately 0.2-mm thickness) were cut to obtain
the DX-loaded polyurethane implants (DX-PUD sheets). Blank
PUD implants were also prepared (PUD sheets).
In Vitro Release of DX From the PUD Sheets
Polyurethane dispersion sheets (Fig. 1A) loaded with different
concentrations of DX (8%, 20%, or 30%, wt/wt) were placed in
24-well tissue culture plates (BD Falcon, Le Pont de Claix,
France) containing 2.0 mL phosphate-buffered saline (PBS, pH
7.4) at 378C (n¼ 6 for each sample). From day 1 to 7, the PBS
was totally retrieved daily, then every week until day 42. At
each time point, after PBS collection, the same volume of fresh
PBS was added to the well. The amount of DX released from
the PUD sheets was assayed by high-performance liquid
chromatography and expressed as the cumulative percentage
of DX leached in the PBS. The average of the obtained
measurements was calculated and used to plot the release
profile curve.
Fourier Transform Infrared Spectroscopy Analysis
of the Degraded PUD Sheets
Blank PUD sheets were placed in 24-well tissue culture plates
containing 2.0 mL PBS at 378C for 20 and 60 days (n ¼ 6 for
each time point). After these periods, degraded PUD sheets
were collected, and the excess surface water was removed
using filter paper. Then, PUD sheets were maintained in a
desiccator at room temperature for 14 days for water
evaporation. The samples were analyzed by Fourier transform
infrared spectrophotometer (FTIR) (Perkin Elmer Spectrum
1000; Saint Paul, MN, USA) using the attenuated total
reflectance (ATR) technique. Each spectrum was a result of
32 scans with a resolution of 4 cm1. The initial PUD sheets
were also analyzed.
ARPE-19 Cell Culture
ARPE-19 cells were cultured in Dulbecco’s modified Eagle’s
medium and Ham’s F12 medium (DMEM/F12; Life Technolo-
gies, Saint-Aubin, France) containing 10% fetal bovine serum
(FBS), and incubated in a humidified atmosphere of 5% CO2
and 95% air at 378C.
In Vitro Cytotoxicity of the Degradation Products
of the DX-PUD Sheets
After sterilization with UV lights for 45 minutes each side, DX-
PUD sheets (30% wt/wt, 30-mm2 surface area) were incubated
with 3 mL PBS at 378C for 4 months. Phosphate-buffered saline
containing the degradation products of DX-PUD was then
collected. ARPE-19 cells were seeded at 43105/well in 24-well
tissue culture plates. Upon confluence, cells were treated with
TABLE 1. Composition of the Aqueous Polyurethane Dispersion
Reagents
Concentration,
% wt/wt
Isophoronediisocyanate (IPDI) 8.58
Polycaprolactone-diol1000 (PCL1000) 4.85
Polycaprolactone-diol2000 (PCL2000) 8.36
Polyethylene glycol (PEG1500) 0.73
2, 2-bis(hydroxymethyl) propionic acid (DMPA) 0.97
Triethylamine (TEA) 0.73
Water 74.70
Hydrazine (HZ) 1.08
FIGURE 1. PUD implant sheet ([A], arrow) and in vitro release profiles
of PUD containing 8%, 20%, or 30% (wt/wt) of the DX (n¼ 6 samples
for each point [B]). The relative standard deviation of all data is lower
than 7%. Scale Bar: 5 mm (A).
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a mixture of fresh culture medium with PBS containing
degradation products (10:1). Control cells were incubated
with culture medium containing fresh PBS. After 1 and 4 days,
cell viability was evaluated using 3-(4,5-dimethylthiazolyl-2)-
2,5-diphenyltetrazolium bromide (MTT) assay (Sigma-Aldrich)
according to manufacturer’s instructions. Experiments were
performed in quadruplicate. The result was expressed as a
percentage relative to the control cells.
Animals
Female Lewis rats (6–8 weeks old; Janvier, Le Genest-Saint-Isle,
France) were kept in pathogen-free conditions with food and
water ad libitum and housed in a 12-hour light/12-hour dark
cycle. All animal experiments were performed in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research and approved by the ethical committee of
Paris Descartes University (ID Ce5/2012/122). Anesthesia was
induced by intramuscular ketamine (50 mg/kg) and xylazine (3
mg/kg). Drops of 1% tetracaine were used for topical
anesthesia.
Implantation of DX-PUD Sheets in the SCS of Rat
Eyes and in the Supraciliary Space of Postmortem
Human Eyes
Sterilized PUD sheets (containing 8%, 20%, or 30% DX) of 135
mm were cut under a surgical microscope. After anesthesia,
the conjunctiva of the rat eye was opened in the superior
temporal quadrant. For suprachoroidal implantation, a 2-mm
full-thickness sclera incision was performed vertically and at 4
mm from the limbus. A tunnel 5 mm long was made between
the sclera and the choroid and parallel to the limbus using a 25-
gauge needle. A PUD sheet was then slid inside the SCS. No
scleral or conjunctival suture was needed. Polyurethane
dispersion sheets were also implanted in the anterior SCS at
1 mm from the limbus. Localization of the polymeric implant
was further examined in vivo using spectral-domain optical
coherence tomography (SD-OCT; Spectralis device; Heidelberg
Engineering, Heidelberg, Germany) adapted for small animals.
We also implanted PUD sheets in the supraciliary space in
two postmortem human eyes. The eyes were collected for
research purposes at 13 hours post mortem in conformity with
the Swiss Federal law on transplantation. All procedures
conformed to the tenets of the Declaration of Helsinki for
biomedical research involving human subjects. A full-thickness
scleral incision was made at 4 mm from the limbus; PUD
implants (2 mm 3 2 cm) were then inserted gently into the
supraciliary space.
Endotoxin-Induced Uveitis
Endotoxin-induced uveitis (EIU) is a well-characterized rat
model for human acute uveitis.16 To evaluate the effect of DX-
PUD implants on EIU, the disease was induced 15 days after
the implantation of the device by a single footpad injection of
100 lL sterile pyrogen-free saline containing 200 mg lipopoly-
saccharide (LPS) from Salmonella typhimurium (Sigma-
Aldrich). The animals received also blank PUD implants.
Subconjunctival injection of 20 lg DX17 and intravitreal
injection of 0.25 lg DX served as positive controls.
Clinical Examination
Twenty-four hours after LPS challenge, rat eyes were examined
using slit-lamp. The intensity of inflammation was classified
from grade 0 to grade 5 as previously described.18 Scoring was
performed by a masked investigator. Rats were then killed and
eyes enucleated for histology, immunofluorescence, and real-
time PCR analyses.
Histology
Rat eyes were fixed in 4% paraformaldehyde (PFA) and 0.5%
glutaraldehyde for 2 hours, dehydrated in a graded alcohol series,
and embedded in historesin (Leica, Heidelberg, Germany).
Sections of 5 lm were obtained using a Leica Jung RM2055
microtome and stained with 1% toluidine blue. Polymorphonu-
clear (PMN) cells, identified by the shape of their nuclei, were
quantified on histologic sections. The analysis was performed on
seven rats (seven eyes) per experimental group with four
different sections per eye at the optic nerve head level.
Human eyes were fixed in formalin for 1 day. The posterior
segment of the eye was then removed. The remaining anterior
segment was fixed in formalin for 2 more days, then dehydrated
in alcohol and embedded in paraffin using a tissue processor
(Citadel 2000, Shandon, Thermo Scientific, Reinach, Switzer-
land). Sections of 5 lm were stained with hematoxylin and eosin.
Immunofluorescence
Eyes were fixed in 4% PFA and incubated with a graded series
of sucrose before being snap frozen in Tissue-Tek optimal
cutting temperature (OCT) compound (Bayer Diagnostics,
Puteaux, France). The following primary antibodies were used
on cryosections: mouse anti-ED1 (1:50; AbDSerotec, Colmar,
France), mouse anti-inducible nitric oxide synthase (iNOS,
1:75; Santa Cruz Biotechnology, Heidelberg, Germany), and
rabbit anti-ionized calcium binding adaptor molecule-1 (anti-
IBA-1, 1:400; Wako, Richmond, VA, USA). The secondary
antibodies (Life Technologies) were Alexa Fluor 488–coupled
goat anti-mouse IgG (1:200), Alexa Fluor 594–coupled goat
anti-mouse IgG (1:200), and Alexa Fluor 488–coupled goat anti-
rabbit IgG (1:200). Negative controls were performed by
omission of primary antibody. ED1-positive macrophage
infiltration in EIU rat eyes was quantified on cross sections at
the optic nerve head level. Four eyes from four rats per group
and four sections per eye were analyzed.
Reverse Transcription and Real-Time PCR
Total RNA was isolated from iris/ciliary body or from neuro-
retina using RNeasy plus Mini Kit (Qiagen, Courtaboeuf,
France). First-strand cDNA was synthesized using random
primers (Life Technologies). Transcription levels of tumor
necrosis factor-a (TNF-a), interleukin 1b (IL-1b), interleukin 6
(IL-6), interleukin 10 (IL-10), cytokine-induced neutrophil
chemoattractant (CINC), iNOS, and occludin (Table 2) were
analyzed by real-time PCR performed in the 7500 Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA) with
either Taqman or SYBR Green detection. The hypoxanthine
phosphoribosyltransferase (HPRT) was used as internal con-
trol. Delta cycle threshold calculation was used for relative
quantification of results.
Statistical Analysis
Data are expressed as the mean 6 SE. Statistical analysis was
performed using GraphPad Prism 5 (GraphPad Software, Inc.,
San Diego, CA, USA). Kruskal-Wallis test followed by Dunn’s
comparison was used. Values of P < 0.05 were considered
significant.
RESULTS
In Vitro Release of the DX From the PUD Sheets
Dexamethasone was released in vitro from PUD sheets
containing different concentrations of the drug (8%, 20%, or
30%, wt/wt) during 42 days (Fig. 1B). The release profiles were
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similar for all DX concentrations. Burst release was observed in
the first week with approximately 55% of DX leached from the
polymeric implants. A sustained drug release was observed
thereafter.
FTIR Analysis of the Degraded PUD Sheets
Fourier transform infrared spectrophotometer spectrum of the
PUD sheets (without DX) showed typical absorption bands, such
as carbonyl group of ester stretching vibration (~1730 cm1),
nitrogen-hydrogen (N-H) bending vibration in secondary amide
(~1640 cm1) (Fig. 2A), and -CH2 stretching vibration (~2950
cm1) (Fig. 2B). Fourier transform infrared spectrophotometer of
the degradation products of the PUD after 20 and 60 days
incubation in PBS showed increased intensities of the bands at
1730 cm1, 1640 cm1, and 2950 cm1. An additional band at
around ~3360 cm1 corresponding to the free hydroxyl
stretching vibrations was also observed (Fig. 2B).
In Vitro Cytotoxicity of the Degradation Products
of the DX-PUD
The ARPE-19 cells were incubated in direct contact with the
degradation products of the DX-PUD accumulated during 4
months in the PBS. After 1 and 4 days of incubation, the ARPE-
19 cells showed 96.69 6 2.27% and 91.1 6 0.6% viability,
compared to the control, respectively.
Biocompatibility of the DX-PUD Implanted in the
SCS of Rat Eyes
The PUD sheets (with or without DX) were successfully
inserted into the posterior and anterior SCS of the rat eyes
(Figs. 3A, 3F), which was confirmed by the in vivo OCT
examination (Fig. 3B). Fifteen days after polymer insertion,
histologic cross section confirmed the presence of the
polymeric implant in the posterior (Fig. 3F) or anterior SCS
(Fig. 3C). Higher magnification showed that the structure of
the retina over the implant was well preserved (Fig. 3D). No
inflammatory cell infiltration was observed in the anterior
segment of the rat eyes (Fig. 3E).
DX-PUD Limited the Severity of Uveitis
Dexamethasone-PUD sheets, containing 8% and 30% (wt/wt) of
the drug, were inserted into the anterior SCS of the eyes 15
days before LPS challenge, so that a sustained release of DX was
obtained in the eyes at the time of uveitis induction.
Dexamethasone controlled released from the polymeric
implants led to a significant reduction of the clinical intensity
of the EIU as compared to the blank PUD and the control group
(EIU), an effect comparable to DX delivered by subconjunctival
or intravitreal injection (Fig. 4A). Polymeric implants loaded
with 30% (wt/wt) DX were then used for the following
experiments. Of note, even with this highest concentration,
the PUD sheets contained only 0.07 mg DX.
Histologic analysis showed that DX controlled released from
the PUD inhibited the inflammatory cell infiltration in the
ocular tissues (Fig. 4D) when compared to the eyes receiving
the blank PUD sheets (Fig. 4C) and to the eyes in the EIU
control group (Fig. 4B). Quantification of inflammatory cells
showed that DX leached from the PUD significantly reduced
the number of PMN (Fig. 4E) and ED1-positive macrophages
(Fig. 4F) when compared to the blank PUD and EIU control
groups.
TABLE 2. Real-Time PCR Primers and Probes
Gene Primer and TaqMan Probe Reference
HPRT1 Rn01527840_m1
TNF-a Rn01525859-g1
IL-1b Rn00676333_g1
IL-6 Rn01410330_m1
iNOS Rn00561646-m1
SYBR Green primer
HPRT1
Sense 50-GCGAAAGTGGAAAAGCCAAGT-30
Antisense 50-GCCACATCAACAGGACTCTTGTAG-30
IL-10
Sense 50-CCTCTGGATACAGCTGCGAC-30
Antisense 50-GTAGATGCCGGGTGGTTCAA-30
CINC
Sense 50-GGGTGTCCCCAAGTAATGGA-30
Antisense 50-CAGAAGCCAGCGTTCACCA-30
FIGURE 2. Fourier transform infrared spectrophotometer spectra of degraded PUD sheets collected after 20 and 60 days of incubation in PBS (A, B).
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DX-PUD Reduced Microglia/Macrophage Activation
To evaluate the effect of DX-PUD on microglia/macrophage
activation and recruitment, we performed immunostaining
with IBA-1 on cryostat sections. Round-shaped IBA-1–positive
microglia/macrophage cells represent activated cells, while
ramified IBA-1–positive microglia/macrophage cells are resting
cells. In DX-PUD implanted eyes, most microglia/macrophages
in the iris and ciliary body were ramified resting cells (Fig. 5C,
inset), whereas in eyes implanted with blank PUD (Fig. 5B) and
in nonimplanted eyes (Fig. 5A), microglia/macrophages were
activated in the iris and ciliary body (arrows). Colabeling of
IBA-1–positive cells with iNOS showed that iNOS was not
expressed by microglia/macrophages in the eyes receiving the
DX-PUD (Fig. 5C, inset). However, in the control groups,
activated microglia/macrophages expressed iNOS (Figs. 5A, 5B,
arrowheads in the insets).
DX-PUD and PUD Modified Cytokine Gene
Expression
In the iris and ciliary body, DX-PUD downregulated the
expression of iNOS and upregulated the expression of anti-
inflammatory cytokine IL-10 (Fig. 6A). Occludin transcripts
were also increased with DX-PUD (not shown). However, no
effect was observed on IL-6 expression (Fig. 6A). In the retina,
DX-PUD significantly reduced the transcripts of IL-1b, IL-6, and
CINC compared to the EIU control group. However, the
reduction of iNOS was not statistically significant (Fig. 6B).
Noticeably, blank PUD also promoted the downregulation of
IL-6 and iNOS and upregulation of IL-10 in the iris and ciliary
body, and reduced CINC in the retina. The expression of TNF-a
was not changed by DX-PUD (not shown).
Feasibility of PUD Implantation in Human Eyes
In order to show the feasibility of PUD implantation in human
eyes, we used postmortem human eyes. After surgical insertion
of PUD sheets (Fig. 7A–C), eyes were fixed immediately for
histologic observation, which showed correct localization of
the implant in the supraciliary space (Figs. 7D, 7E) as desired.
DISCUSSION
The treatment of retinal diseases associated with macular
edema requires intravitreal injections of biologics or steroids,
allowing for high and prolonged drug concentration in the
vitreous cavity. However, to maintain therapeutic drug
concentration in the target site, repeated intravitreal injections
are often required, which are often associated with poor
compliance and discomfort, risks of vitreous hemorrhage,
retinal detachment, intraocular pressure elevation,19 cataract
progression, endophthalmitis,20,21 and ocular toxicity.22
The strategies to improve the bioavailability of drugs to the
posterior segment of the eye and to minimize the risks of
repeated intravitreal injections include the development of
control–release intraocular drug–incorporated implants. In this
study, we report a biodegradable PUD polymer releasing DX
progressively and implanted in the anterior SCS of rat eyes that
successfully limits the severity of EIU by decreasing the
inflammatory cell infiltration, reducing the microglia/macro-
phage activation, and modulating the cytokine expression.
The polyurethane applied to design these implantable
devices was synthesized using poly(caprolactone) (PCL) and
poly(ethylene glycol) (PEG) as soft segment and urethane as
hard segment. The hard segment provides dimensional stability
FIGURE 3. Ocular biocompatibility of the PUD and DX-PUD implants. (A) Biomicroscopy shows PUD sheet implanted behind the limbus (junction
between the cornea and sclera) of the rat eye. (B) Optical coherence tomography performed on the same eye after surgery shows the position of the
PUD implant in the suprachoroidal space under the peripheral retina. (C) Fifteen days after implantation, histologic section confirms the localization
of the DX-PUD implant in the anterior suprachoroidal space close to the ciliary body (CB). (D) Higher magnification of the retinal area in the lower
rectangle in (C) shows that the retina above the DX-PUD maintains its normal structure. (E) Higher magnification of the CB in the upper rectangle
in (C) shows no inflammatory cell infiltration. (F) Retinal morphology remains normal 15 days after suprachoroidal implantation of DX-PUD in the
posterior segment of the rat eye. Scale Bars: 200 lm (C, F); 20 lm (D, E). Chor, choroid; RPE, retinal pigment epithelium; ONL, outer nuclear layer;
OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer.
Anti-Inflammatory Effect of DX-PUD on EIU IOVS j April 2016 j Vol. 57 j No. 4 j 1675
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/935164/ on 10/18/2017
by acting as reinforcing filler and as thermally reversible
crosslink. The soft segment provides the elastomeric character
to the polymer backbone.23,24 The PCL presents labile aliphatic
ester linkages, which can be hydrolyzed in the biological
environment. However, degradation rate of PCL alone is rather
slow due to its hydrophobicity and semicrystalline structure.25
To accelerate polymer biodegradation, PEG can be introduced
to increase hydrophilicity and aqueous absorption.26,27 The
FIGURE 4. DX-PUD implants limit the severity of EIU in the rat eyes. (A) DX-PUD implants decrease the clinical score of uveitis 24 hours after LPS
challenge in a dose-dependent manner. This effect is comparable to DX injected in the vitreous (IVT, 0.25 lg) or in the subconjunctival space (SC,
20 lg). n¼13 for EIU, 12 for EIUþPUD, 4 for EIUþDX-PUD 8% (wt/wt), 6 for EIUþDX-PUD 30% (wt/wt), 8 for EIUþIVT-DX, and 5 for EIUþSC-DX. (B–
D) Histologic sections of rat eyes show infiltration of inflammatory cells (arrows) in the anterior segment of EIU (B) and PUD-implanted EIU eyes
(C), while in DX-PUD implanted eyes, fewer inflammatory cells are observed. Scale Bar: 50 lm. CB, ciliary body. (E) Quantification of PMN
leukocytes on histologic sections of rat eyes shows that DX-PUD implants reduce PMN infiltration as compared to PUD-implanted EIU eyes or EIU
group (n¼ 7 rats per condition); (F) Quantification of ED1-positive macrophages on immunofluorescence sections shows that DX-PUD implants
also decrease macrophage infiltration as compared to nonimplanted and PUD-implanted EIU eyes (n¼ 4 rats per condition). *P < 0.05; **P < 0.01.
FIGURE 5. DX-PUD implants reduced microglia/macrophage activation in EIU rat eyes. (A) IBA-1 immunostaining (red) shows that in the EIU
control group, most microglia/macrophages in the iris/ciliary body display a round shape (arrows), suggesting microglia/macrophage activation.
Colabeling of IBA-1 with iNOS (green) shows that these round IBA-1–positive cells express iNOS (inset, arrowheads). (B) In the EIU eyes receiving
blank PUD implants, most IBA-1–positive microglia/macrophages (arrows) are also in a round activated shape, colocalizing with iNOS (inset,
arrowheads). (C) In the eyes receiving DX-PUD implants, most IBA-1–positive cells are in a resting ramified shape, and iNOS is not expressed by
these cells (inset). Scale Bar: 20 lm.
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FIGURE 6. Quantitative PCR of cytokine expression in the iris/ciliary body and in the retina of EIU rats. (A) In the iris and ciliary body, DX-PUD
implants downregulate the expression of iNOS and upregulate the expression of IL-10. Blank PUD implants downregulate the expression of IL-6 and
iNOS and upregulate the expression of IL-10. (B) In the retina, DX-PUD implants reduce significantly the transcripts of IL-1b, IL-6, and CINC; the
decrease in iNOS mRNA is not significant. Blank PUD implants downregulate CINC. HPRT was used as housekeeping gene. Data are expressed
relative to the EIU control (n¼ 5 rats per condition). *P < 0.05; **P < 0.01, ***P < 0.001.
FIGURE 7. Supraciliary implantation of PUD in postmortem human eye. (A–C) Surgical procedure of supraciliary implantation of the PUD sheet. (D)
Histology of the anterior segment of the implanted postmortem human eye shows that the PUD is located between the sclera and the pars plana of
ciliary body (CB). (E) Higher magnification of the rectangle area in (D). Arrow in (E) indicates the sclera incision.
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FTIR spectra of the degraded polyurethane after 20 and 60 days
of incubation demonstrated the presence of an additional band
at around 3360 cm1, equivalent to the free hydroxyl
stretching vibrations, and the existence of an intensified band
at around 1730 cm1, indicating the augmentation of free
carbonyl groups. These bands could be attributed to the
aqueous hydrolysis of the ester group of the PCL from 20 to 60
days, resulting in continuous formation of free carbonyl groups
and hydroxyls associated to aliphatic groups (alcohol).
Hydrolysis of the ester bonds further enhances the hydrophilic
nature of the soft domains,26 which increases their compati-
bility with the polar hard segments, leading to higher levels of
mixing of these segments. As a consequence, the urethane
linkages of the hard segments are deeply exposed to diffused
water, inducing their hydrolysis, and possible chain scissions in
the polyurethane. These cleavages are evidenced by the
increased intensity of the secondary amide at around 1640
cm1 present in the hard segments.
The degradation of PUD polymer is also an important
characteristic that influences the release profile of the loaded
drug, mainly when this drug is highly hydrophobic as is the
DX. During the first 7 days, a burst release of approximately
55% DX from the implantable sheets was observed. In this
stage, water penetrates into preexistent channels and pores of
the polyurethane and dissolves the DX. The presence of
hydrophilic PEG also helps water penetration.15 From 8 to 42
days, a controlled and sustained release of DX from the
polymer was achieved. During this period, higher aqueous
diffusion induced by PEG in the soft segments leads to the
hydrolysis of the ester bonds of the PCL in the soft segments
and the urethane linkages in the hard segments, producing
chain scissions of the polyurethane. As a result, new channels
and pores connecting the surface to the inside of the matrix
are generated for drug diffusion. Therefore, the PUD sheets
controlled release the DX in a complex kinetic mechanism,
involving the diffusion of the drug and erosion of the
polymeric chains.
The DX-PUD sheets were submitted to a 4-month period of
biodegradation, and the collected by-products have been
shown to be noncytotoxic to ARPE-19 cells. The reagents
applied as precursors of this polyurethane were carefully
selected so that the hydrolytic biodegradation process was
favorable, and the degradation by-products were previously
supposed to be noncytotoxic to ARPE-19 cells.26 Furthermore,
DX is not supposed to present a significant degradation at the
available conditions, since it is chemically stable after
reconstitution in 0.9% saline injection for a long period.28
The viability of ARPE-19 cells incubated with by-products of
DX-PUD is comparable to that of cells incubated with by-
products of blank PUD,26 indicating nontoxicity of the
accumulated DX released from PUD sheets. The biocompati-
bility of blank PUD has been previously shown in rat eyes after
15 days of suprachoroidal implantation.13 We did not find
additional retinal toxicity induced by DX released from PUD
sheets.
Endotoxin-induced uveitis is a well-characterized rat model
for mimicking the pathologic conditions in human acute
uveitis. Footpad injection of LPS in Lewis rats induces an acute
anterior uveitis involving also the posterior segment.16,29 We
chose to position the PUD sheet posterior to the limbus and
just adjacent to the anterior uvea, where inflammation begins.
The structure and physical properties of the material allow
design of thin and foldable implant sheets that are rigid enough
to serve as a guide for suprachoroidal implantation.
In EIU, infiltration of monocytes in the iris is observed as early
as 2 hours after LPS injection, followed by a massive myeloid cell
infiltration, mostly PMN, at 4 to 6 hours. After this initial peak, a
massive infiltration of cells into the iris and ciliary body occurs at
24 hours.30,31 Macrophages and neutrophils are the main source
of the proinflammatory cytokines leading to anterior uveal
inflammation and breakdown of the blood–aqueous barrier.31
Tumor necrosis factor-a and IL-1 are produced early by resident
macrophages/microglia responding to endotoxin. Tumor necro-
sis factor-a and IL-1 can induce IL-6, which contributes to the
inflammation including activation of macrophages.32 Cytokine-
induced neutrophil chemoattractant is the rat equivalent of
human IL-8, a CXC chemokine that is increased in aqueous
humor at the time of cell infiltration.33 Later in the course of EIU,
anti-inflammatory cytokines including IL-10 participate in
downregulation of proinflammatory mediators and inhibit
inflammatory cell infiltration in EIU.34 Continuous high expres-
sion of IL-10 in the eye has been also shown to play an important
role in the mechanism of LPS tolerance in rat EIU.35 Inducible
NOS is produced by infiltrating neutrophils and monocytes and
resident macrophages as well as by vascular endothelium. Nitric
oxide (NO) synthesis by iNOS can also be induced by LPS or
cytokines such as TNF-a and IL-1. Nitric oxide may contribute to
breakdown of the blood–aqueous barrier during EIU.31 We
showed that PUD sheets releasing DX reduce EIU by preventing
infiltration of polymorphonuclear cells and macrophages.
Activation of macrophages/microglia is also inhibited with
reduced production of iNOS by these cells. Dexamethasone-
PUD sheets induce anti-inflammatory cytokines and inhibit
production of proinflammatory cytokines and chemokines,
contributing to prevention of uveitis. It is interesting that the
blank PUD alone regulates cytokine and chemokine expression.
Further investigations are required to identify the degradation
products of PUD that may have anti-inflammatory potential.
Because the rat eye has anatomic characteristics far
different from the human eye, we have also evaluated the
feasibility of PUD implantation in the supraciliary space
showing an easy access to this site. To target the posterior
retina and choroid, such an implantation site might not be
optimal; but for the treatment of uveitis, corticosteroids and/or
immunosuppressive could be delivered locally very close to
the uveal tissue.
In conclusion, biocompatible anterior suprachoroidal PUD
sheets allow controlled release of incorporated DX that
prevent inflammatory events of EIU. They could also be easily
implanted into the SCS of the posterior segment to potentially
target retinal/choroidal diseases.
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